CA2442742A1 - Quinazoline derivatives - Google Patents

Quinazoline derivatives Download PDF

Info

Publication number
CA2442742A1
CA2442742A1 CA002442742A CA2442742A CA2442742A1 CA 2442742 A1 CA2442742 A1 CA 2442742A1 CA 002442742 A CA002442742 A CA 002442742A CA 2442742 A CA2442742 A CA 2442742A CA 2442742 A1 CA2442742 A1 CA 2442742A1
Authority
CA
Canada
Prior art keywords
group
hydrogen atom
alkyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002442742A
Other languages
English (en)
French (fr)
Inventor
Yasunori Kitano
Eiji Kawahara
Tsuyoshi Suzuki
Daisuke Abe
Masahiro Nakajou
Naoko Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2442742A1 publication Critical patent/CA2442742A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002442742A 2001-02-21 2002-02-21 Quinazoline derivatives Abandoned CA2442742A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001-45827 2001-02-21
JP2001045827 2001-02-21
JP2001353525 2001-11-19
JP2001-353525 2001-11-19
PCT/JP2002/001575 WO2002066445A1 (en) 2001-02-21 2002-02-21 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
CA2442742A1 true CA2442742A1 (en) 2002-08-29

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002442742A Abandoned CA2442742A1 (en) 2001-02-21 2002-02-21 Quinazoline derivatives

Country Status (10)

Country Link
US (2) US7294629B2 (enExample)
EP (1) EP1369418B1 (enExample)
JP (1) JP4285996B2 (enExample)
KR (1) KR100861486B1 (enExample)
CN (1) CN1264824C (enExample)
AT (1) ATE475652T1 (enExample)
CA (1) CA2442742A1 (enExample)
DE (1) DE60237145D1 (enExample)
TW (1) TWI309647B (enExample)
WO (1) WO2002066445A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7569577B2 (en) 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
JP4036885B2 (ja) * 2003-09-19 2008-01-23 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20070043010A1 (en) * 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
US20050165031A1 (en) * 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
WO2005051924A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation キナゾリン誘導体及びその製造方法
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
EP1792898A1 (en) * 2004-09-01 2007-06-06 Mitsubishi Pharma Corporation Molecular chaperone function regulator
CN101124228B (zh) 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
CN101163684B (zh) * 2005-02-23 2012-08-29 盐野义制药株式会社 具有酪氨酸激酶抑制作用的喹唑啉衍生物
EP1856095B1 (en) 2005-02-26 2011-08-24 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
JP4993205B2 (ja) * 2005-03-30 2012-08-08 塩野義製薬株式会社 チロシンキナーゼ阻害作用を有するピリミジン誘導体
US7820683B2 (en) 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
CA2644494A1 (en) * 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
EA201201289A1 (ru) 2010-03-16 2013-08-30 Мерк Патент Гмбх Морфолинилхиназолины
KR20200003933A (ko) * 2011-03-04 2020-01-10 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
AU2014287016B2 (en) 2013-07-11 2018-11-01 Acea Biosciences Inc. Pyrimidine derivatives as kinase inhibitors
WO2017059702A1 (en) 2015-10-09 2017-04-13 Acea Biosciences, Inc Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
KR102602820B1 (ko) * 2017-01-30 2023-11-15 시오노기세이야쿠가부시키가이샤 퀴나졸린 유도체를 함유하는 고형 제제
JP2020516682A (ja) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN114787150A (zh) * 2019-08-15 2022-07-22 黑钻治疗公司 炔基喹唑啉化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−Ｌ−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2005051924A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Pharma Corporation キナゾリン誘導体及びその製造方法

Also Published As

Publication number Publication date
EP1369418A1 (en) 2003-12-10
KR20030086269A (ko) 2003-11-07
JPWO2002066445A1 (ja) 2004-06-17
EP1369418A4 (en) 2005-09-14
CN1492860A (zh) 2004-04-28
EP1369418B1 (en) 2010-07-28
US7294629B2 (en) 2007-11-13
CN1264824C (zh) 2006-07-19
KR100861486B1 (ko) 2008-10-02
JP4285996B2 (ja) 2009-06-24
ATE475652T1 (de) 2010-08-15
US20070265260A1 (en) 2007-11-15
DE60237145D1 (de) 2010-09-09
TWI309647B (enExample) 2009-05-11
US20040116422A1 (en) 2004-06-17
WO2002066445A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
CA2442742A1 (en) Quinazoline derivatives
CA2218945C (en) 4-aminoquinazoline derivatives
US6225318B1 (en) 4-aminoquinazolone derivatives
JPWO2002066445A6 (ja) キナゾリン誘導体
US6187786B1 (en) Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6399615B1 (en) Farnesyl protein transferase inhibitors
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
AU2011264209B2 (en) Cyanoquinoline derivatives
SK70498A3 (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2- -quinolinone derivatives
NZ286263A (en) 4 (substituted phenylamino) quinazoline derivatives, preparation and pharmaceutical compositions thereof
BRPI0608160A2 (pt) anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
PL218769B1 (pl) Podstawione 3-cyjanochinoliny lub ich farmaceutycznie dopuszczalne sole jako inhibitory białkowych kinaz tyrozynowych
HUP0002954A2 (hu) Farnezil-protein transzferáz új N-szubsztituált-karbamid inhibitorai
BRPI0610144A2 (pt) método de preparar um 3-cianoquinolina substituìda; composto representado pela fórmula i; e composto, representado pela fórmula ii
JP2003528880A (ja) 三環系タンパクキナーゼ阻害薬
EP1100788A1 (en) Substituted quinazoline derivatives
CN101638383B (zh) 喹啉衍生物及其药物组合物和用途
KR100272471B1 (ko) 신규의 피리미딘 유도체 및 그의 제조방법
US6071907A (en) Tricyclic compounds useful as FPT inhibitors
CA2293358C (en) Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
US6426352B1 (en) Sulfonamide inhibitors of farnesyl-protein transferase
HUP0004521A2 (hu) Farnezil-protein transzferáz inhibitorokként alkalmazható benzo[5,6]-ciklohepta-piridil-(ciklusos karbamid- és laktám)-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
CA2261724C (en) Novel tricyclic n-cyanoimines useful as inhibitors of farnesyl-protein transferase
CN103554091B (zh) 喹唑啉衍生物及其制备方法和用途
HUP0004806A2 (hu) Farnezil-protein transzferáz gátlására alkalmazható benzo [5,6]ciklohepta[1,2-b]piridin-származékok és a vegyületeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued